Alaska Air Q3 Outlook Misses Estimates as Higher Fuel Costs Weigh on Profit Forecast 
Trump Threatens Iran With 'Major Military Punishment' as Red Sea Attacks Push Oil Above $100 
Japan Yen Slides Past 163 as Middle East Tensions Lift US Dollar, Oil Prices 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
Asian Stocks Rally on AI Spending Optimism as Middle East Tensions Push Oil to Six-Week High 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
Gold Price Holds Weekly Gain as Middle East Tensions and Fed Rate Outlook Drive Market 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
India FMCG Q1 Earnings Preview: Higher Input Costs Likely to Weigh on Profit Margins 
Iran Rejects U.S.-Backed Ceasefire as Trump Escalates Military Threats, Oil Tops $100 
Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership 
European Stocks Flat as Oil Tops $100, Trump Tariffs Fuel Inflation Fears 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
GE Vernova Q2 Revenue Tops Estimates as Earnings Miss, Shares Slide Despite Higher 2026 Outlook 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
Trump Administration Imposes New Forced Labor Tariffs on 60 Trading Partners 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
